Isomorphic Labs Raises $5 Billion Series C to Push AI Drugs Into Trials
Isomorphic Labs raised $5 billion in a Series C co-led by Greenoaks and Sequoia to fund its IsoDDE drug-design engine and move AI-designed therapeutic candidates into clinical trials.
By Daniel Okafor
3 min read

What's News
- Isomorphic Labs raised $5 billion in Series C funding announced on November 17, 2026, co-led by Greenoaks and Sequoia Capital.
- The round follows a $2.1 billion Series B from May 12, 2026, and a $600 million first external round from March 31, 2025.
- Every existing investor returned, including Thrive Capital, GV, CapitalG, Temasek and the UK Sovereign AI Fund, plus new money from Andreessen Horowitz and Alphabet.
- Isomorphic reports positive preclinical outcomes in wholly owned oncology and immunology programs and in partnerships with Novartis, Eli Lilly and Johnson & Johnson.
- The Novartis collaboration began in January 2024 on three targets and expanded in February 2025 with up to three more research programs.
Isomorphic Labs raised $5 billion in Series C funding on November 17, 2026, to push its AI-designed drug candidates toward human trials. Greenoaks and Sequoia Capital co-led the oversubscribed round. Andreessen Horowitz joined as a new investor, alongside Alphabet, which added another significant check.
Every existing investor came back. The returning group includes Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The round is the largest yet for the company, which spun out of Alphabet's DeepMind research heritage and now sits on roughly $7.7 billion in disclosed external funding across three rounds.
The money has three jobs. Isomorphic will extend IsoDDE, its proprietary drug-design engine. It will expand into new areas of biology and build global infrastructure for AI-led bioengineering. It will also construct translational and clinical-development capacity to move candidates into patient testing.
Founder and CEO Demis Hassabis framed the plan in the funding release: "This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients."
What is IsoDDE?
IsoDDE is the machine at the center of the business. The company describes it as a collection of AI simulation models built to handle different therapeutic areas and types of drugs. The system searches chemical space to design and refine molecules with drug-like properties. Proprietary agents navigate and reason through complex biology alongside the molecular design work.
The engine is already producing results, according to the company. Isomorphic reports positive preclinical outcomes from wholly owned oncology and immunology programs and from partnered work. Those results form the basis for its planned move into clinical trials.
How did the company get here?
The Series C follows a $2.1 billion Series B announced on May 12, 2026, led by Thrive Capital. Alphabet and GV participated, alongside new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. Thrive also led the earlier $600 million first external round announced on March 31, 2025, which included GV and follow-on capital from Alphabet.
The trajectory is steep. In 20 months the company moved from a $600 million debut to a $5 billion raise, with each round adding strategic and sovereign capital.
Who are the pharma partners?
Isomorphic's partnership portfolio spans three major pharmaceutical companies:
- Eli Lilly: a collaboration on small-molecule therapeutics against undisclosed targets.
- Johnson & Johnson: a multi-target collaboration spanning both small molecules and biologics.
- Novartis: small-molecule research against three challenging targets, begun in January 2024 and expanded in February 2025 with up to three additional research programs.
Together, these deals pair company-owned oncology and immunology work with partnered research across different drug modalities. The Novartis relationship, now running for nearly three years, is the oldest and most expanded of the three.
Isomorphic is also building a partner ecosystem to study the mechanisms that drive disease, extending its reach beyond individual drug programs.
What is the central test for the $5 billion?
The round gives Isomorphic the resources to develop its models and its clinical-development infrastructure at the same time. That dual build is the point: AI-designed molecules mean little without the machinery to test them in patients.
The company's central test, as the announcement itself frames it, is whether reported preclinical progress translates into clinical evidence as candidates from owned and partnered programs enter human trials. No candidate has reached that stage yet. The first data from human studies will determine whether the $7.7 billion bet on computational drug design produces tangible impact for patients — or stays a preclinical promise.
Source: unite.ai
More from Daniel Okafor
Show full bio
Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.
2,206 articles